Aurora Maintains Shareholder Recommendation to Take No Action at this Time as Curaleaf Has Yet to File Their Revised Hostile Bid
Aurora Cannabis (ACB) advises shareholders to take no action on Curaleaf's hostile takeover bid, which has yet to be formally revised. Curaleaf's initial offer of $5.00 per share (0.4013 shares + $1.00 cash) is under review by Aurora's special committee. Aurora expects Curaleaf to provide pro forma financials and extend the bid timeline. The board will issue a formal recommendation once the review is complete. Shareholders have until December 4, 2026, to consider their options.
How this was made

The 30-second read
Why it matters
The announcement creates uncertainty for both companies, influencing share price expectations and sector sentiment.
Market read
The pending hostile bid and Aurora's recommendation generate short-term trading interest and sector-wide attention.
What to watch
Regulatory approval timelines and potential antitrust scrutiny could delay or block the transaction.
Background
Aurora Cannabis responded to Curaleaf's announced intention to revise its hostile takeover bid, extending the deadline and urging shareholders to hold.
Ticker impact
Aurora Cannabis (ACB) advises shareholders to take no action as Curaleaf's revised hostile bid has not been filed, extending the bid deadline to Dec 4.
downward pressure as investors await the formal revised offer.
The company has not received the revised bid materials; the special committee will review once received, creating uncertainty.
Market effects
The cannabis sector may see heightened volatility as a major takeover attempt unfolds.
North American cannabis stocks could be affected by the bid dynamics.
Limited to investors focused on cannabis and M&A activity.
Counterpoint
If the revised bid fails to materialize, Aurora shares could rebound on the back of defensive positioning.
Key entities
- CompanyAurora Cannabis Inc.
Canadian cannabis producer (TSX: ACB, NASDAQ: ACB).
- CompanyCuraleaf Holdings, Inc.
U.S. cannabis operator (NASDAQ: CURA) pursuing a hostile bid for Aurora.
